NCT02772003View on ClinicalTrials.gov

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

March 4, 2020

Study Completion Date

March 6, 2026

Conditions
Chronic HepatitisHepatitis C InfectionHepatocellular Carcinoma
Interventions
BIOLOGICAL

Electroporation-Mediated Plasmid DNA Vaccine Therapy

Undergo electroporation

BIOLOGICAL

HCV DNA Vaccine INO-8000

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rocakinogene Sifuplasmid

Given IM

Trial Locations (5)

19140

Temple University Hospital, Philadelphia

44106

Case Western Reserve University, Cleveland

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

00936

University of Puerto Rico, San Juan

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

National Cancer Institute (NCI)

NIH